Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORACLE phase 3 trial of oral azacitidine versus investigator's choice therapy in relapsed or refractory angioimmunoblastic T-cell lymphoma
2024-519336-16-00Phase 3Completed
- Sponsor
- LYSARC
- Start
- Oct 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azacitidine, bendamustine and gemcitabine in angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and T-cell lymphoma follicular helper (TFHL) (2 arms), sponsored by LYSARC. Primary endpoint: Progression-free survival. Started Oct 2018; status: completed.
02
Drugs
azacitidinebendamustinegemcitabine
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)T-cell lymphoma follicular helper (TFHL)
Beyond the preview
Go deeper on 2024-519336-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519336-16-00.